CAR T Cell Therapy for Lymphoma, Leukemia, and Myeloma: Experts Answer Clinician Questions

In this episode, Michael R. Bishop, MD; Daniel J. DeAngelo, MD, PhD; and Noopur Raje, MD, answer clinician questions on current best practices and emerging applications with CAR T-cell therapy, with topics including:Optimal use of approved CAR T-cell therapies for lymphoma and ALLInvestigational CAR T-cell therapies for multiple myelomaManaging CAR T-cell therapy–related toxicitiesPresenters:Michael R. Bishop, MDProfessor of MedicineSection of Hematology/OncologyDirector, Cellular Therapy ProgramUniversity of ChicagoChicago, IllinoisDaniel J. DeAngelo, MD, PhDProfessor of MedicineDepartment of MedicineHarvard Medical SchoolChief, Division of LeukemiaDepartment of Medical OncologyDivision of Hematologic MalignanciesDana‐Farber Cancer InstituteBoston, MassachusettsNoopur Raje, MDProfessor of MedicineHarvard Medical SchoolDirectorCenter for Multiple MyelomaMassachusetts General Hospital Cancer CenterBoston, MassachusettsContent based on an online CME program supported by educational grants from Celgene Corporation and Legend Biotech USA Inc.Link to full program:https://bit.ly/3iyt5zQ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.